New approval of SKYRIZI® (risankizumab) for ulcerative colitis [1]

Ulcerative colitis (UC) can lead to progressive intestinal damage and massive restrictions in the daily lives of those affected [2]. With the approval of SKYRIZI® (risankizumab), a new first-line therapy is now available to UC patients [1]. Data from pivotal phase 3 clinical trials show rapid and sustained efficacy and make long-term goals such as mucosal healing achievable in up to 76% of patients without prior biologic failure^$ possible [3, 4].